Literature DB >> 11708434

Urticaria and angioedema from cyclooxygenase-2 inhibitors.

P S Kelkar1, J H Butterfield, H G Teaford.   

Abstract

Cyclooxygenase-2 (COX-2) inhibitors celecoxib and rofecoxib have generally been well tolerated. It has been unclear if specific COX-2 inhibitors would cross react with acetylsalicylic acid and typical nonsteroidal antiinflammatory drugs to cause urticaria or angioedema. There are no reports in the literature of hives or angioedema resulting from their use. We describe 3 patients who developed urticaria and/or angioedema from COX-2 inhibitors. With the increasing use of COX-2 inhibitors, one needs to be aware of these side effects and of possible cross reactivity between celecoxib and rofecoxib.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11708434

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

1.  Risk of hospitalization for angio-oedema among users of newer COX-2 selective inhibitors and other nonsteroidal anti-inflammatory drugs.

Authors:  Amy Downing; Jacob Jacobsen; Henrik T Sorensen; Joseph K McLaughlin; Soren P Johnsen
Journal:  Br J Clin Pharmacol       Date:  2006-08-30       Impact factor: 4.335

2.  Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.

Authors:  Deborah Layton; Lynda V Wilton; Saad A W Shakir
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

Review 3.  COX-2 inhibitors: a CLASS act or Just VIGORously promoted.

Authors:  Samir Malhotra; N Shafiq; P Pandhi
Journal:  MedGenMed       Date:  2004-03-23

Review 4.  Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature.

Authors:  Tobias Bernd Weberschock; Sylke-Monina Müller; Sandra Boehncke; Wolf-Henning Boehncke
Journal:  Arch Dermatol Res       Date:  2007-05-11       Impact factor: 3.017

5.  COX-2: where are we in 2003?--distinction from NSAIDs becoming blurred.

Authors:  Richard Day
Journal:  Arthritis Res Ther       Date:  2003-02-27       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.